Clinical data
Routes of
ATC code none
Legal status
Legal status
  • Development terminated
CAS Number 76956-02-0
PubChem (CID) 55473
ChemSpider 50093
UNII X16K5179V5
Chemical and physical data
Formula C19H29N5O2
Molar mass 359.47 g/mol
3D model (Jmol) Interactive image

Lavoltidine (INN,[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[3][4]

See also


  1. "WHO Drug Information. Vol 4, No. 3, 1990. International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). World Health Organization. p. 7. Retrieved 12 January 2016.
  2. "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
  3. Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
  4. Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
This article is issued from Wikipedia - version of the 10/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.